Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system

Experimental and Therapeutic Medicine

Volumn 1, Issue 6, 2010, Pages 943-946

  Jin, Juyoun ^a   Joo, Kyeung Min ^a,b   Nam, Yoonhee ^c   Kim, Dae Hyun ^d   Lee, Se Jeong ^a   Jo, Mi Young ^a   Jin, Younggeon ^a   Kim, Hyeong Seok ^a   Seo, Soo Won ^a   Kim, Seok Jin ^a   Nam, Do Hyun ^a   Kim, Won Seog ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Gwacheon Foreign Language High School   (South Korea)

^d Korea Minjok Leadership Academy   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; RITUXIMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LYMPHOMA; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE;

EID: 78049274199     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2010.143     Document Type: Article

References (13)

1. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833, 1998.
2. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al: IDEC-C2B8: results of a phase Imultiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15: 3266-3274, 1997.
3. Neuwelt EA, Barnett PA, McCormick CI, Remsen LG, Kroll RAand Sexton G: Differential permeability of a human brain tumor xenograft in the nude rat: impact of tumor size and method of administration on optimizing delivery of biologically diverse agents. Clin Cancer Res 4: 1549-1555, 1998.
4. Neuwelt EA: Mechanisms of disease: the blood-brain barrier. Neurosurgery 54: 131-142, 2004.
5. Herrlinger U, Kuker W, Uhl M, et al: NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 57: 843-847, 2005.
6. Abrey LE, Yahalom J and DeAngelis LM: Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18: 3144-3150, 2000.
7. DeAngelis LM, Seiferheld W, Schold SC, Fisher B and Schultz CJ: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20: 4643-4648, 2002.
8. Enting RH, Demopoulos A, DeAngelis LMand Abrey LE: Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63: 901-903, 2004.
9. Wong ET, Tishler R, Barron Land Wu JK: Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 101: 139-145, 2004.
10. Jahnke K, Muldoon LL, Varallyay CG, et al: Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma. Neuro Oncol 11: 503-513, 2009.
11. Wang W, Kardosh A, Su YS, Schonthal AHand Chen TC: Efficacy of celecoxib in the treatment of CNS lymphomas: an in vivo model. Neurosurg Focus 21: E14, 2006.
12. Barnett PA, Roman-Goldstein S, Ramsey F, et al: Differential permeability and quantitative MRimaging of a human lung carcinoma brain xenograft in the nude rat. Am J Pathol 146: 436-449, 1995.
13. Neuwelt EA, Barnett PA, Hellstrom KE, Hellstrom I, McCormick CIand Ramsey FL: Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. J Nucl Med 35: 1831-1841, 1994.